End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,375 KRW | +0.64% | +1.50% | -38.39% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The stock, which is currently worth 2024 to 1583.35 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.39% | 128M | - | ||
-16.83% | 8.62B | B+ | ||
+79.26% | 4.6B | C+ | ||
+16.38% | 2.98B | B- | ||
-3.15% | 2.66B | - | ||
-4.20% | 1.98B | C- | ||
-52.37% | 1.91B | B- | ||
-13.53% | 1.56B | A- | ||
+21.59% | 1.25B | B+ | ||
-47.00% | 1.08B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A084650 Stock
- Ratings LabGenomics Co., Ltd.